Pfizer Korea recently obtained full approval for its Covid-19 oral antiviral treatment Paxlovid from the Ministry of Food and Drug Safety (MFDS), but concerns have been raised about vaccine damage compensation for its Covid-19 vaccine, Comirnaty.Along with this concern, Pfizer Korea held a press mee
Kwangdong Pharmaceutical said that it has partnered with Chiesi Farmaceutici, an Italy-based global pharmaceutical company, for the exclusive distribution of the latter's three rare disease drugs in Korea.Under the accord, Chiesi will supply Raxone, Elfabrio, and Lamzede.Raxone is an original drug i
Sillajen said Monday its clinical study on the combination of Pexa-Vec and Libtayo has been accepted as a poster at the European Society for Medical Oncology Annual Meeting 2023 (ESMO 2023) in Madrid in October.In 2017, Sillajen entered into a collaboration agreement with Regeneron for the clinical
Researchers from Yonsei Cancer Center discovered a three-drug combination -- comprising HER2-targeted therapy, trastuzumab, and ramucirumab plus paclitaxel, the existing standard of care -- which demonstrated superior efficacy and fewer side effects than other agents in patients with HER2-positive a
SK chemicals said Thursday that it signed a global contract manufacturing organization (CMO) agreement with AstraZeneca for the supply of Sidapvia. Sidapvia is a combination of Forxiga (ingredient: dapagliflozin) and sitagliptin, approved in Korea to treat type 2 diabetes in adults aged 18 years and
Targeted cancer therapies such as T cell bispecific antibodies, sometimes called bispecific T cell engagers, have been attracting more attention for their ability to hone in on the cancerous cells, and domestic companies are ready to get in on the action.Last year, the U.S. FDA approved Immunocore’s
Osang Healthcare (OHC), which recently signed a comprehensive business cooperation agreement with Yuhan Corp., has emerged as the second largest shareholder of one of the latter’s subsidiaries.Osang Healthcare said Thursday that the company has completed paying money for the three-party capital incr
The recent mislabeling of medicines by Hyundai Pharm and other incidents of drug mix-ups are threatening consumers’ health, consumer groups said.Issuing a statement Wednesday, the Citizens United for Consumer Sovereignty (CUCS), a consumer advocacy group, criticized Hyundai Pharm’s labeling errors,
Astellas Korea has officially launched Padcev (ingredient: enfortumab vedotin), which treats locally advanced or metastatic urothelial cancer.Padcev, an antibody-drug conjugate (ADC) that targets Nectin-4, received approval from the Ministry of Drug Safety as a monotherapy in March. It has a categor
Pfizer's first-in-class CDK4/6 inhibitor, Ibrance (palbociclib), has received an expanded indication in Korea.It can now be used as first-line endocrine therapy in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast
GC Biopharma said on Wednesday that its quadrivalent flu vaccine, GC FLU Quadrivalent inj., has been approved by the Egyptian Drug Authority (EDA), marking the company's first approval on the African continent. Egypt has one of the largest pharmaceutical markets in the African region, with the flu v
Multinational pharmaceutical companies are partnering with government agencies or pharmaceutical industry associations to bolster innovation in the Korean biotech sector.These support programs aim to bridge the gap between research and market access, providing essential resources, mentorship, and fu
In the ever-evolving landscape of pharmaceutical logistics, Marken aims to become a trailblazer, offering logistic services tailored exclusively to the biopharma industry.To get more in-depth knowledge about the sector, Korea Biomedical Review recently met with Mary Ahn, Country Manager of Marken Ko
Prestige BioPharma, a Singapore-based pharmaceutical company specializing in antibody biopharmaceuticals, said on Tuesday that it joined the Cancer Moonshot Project promoted by U.S. President Joe Biden. This is the first time a Kospi-listed company and antibody drug developer has joined the Cancer M
HLB said the U.S. Food and Drug Administration (FDA) has initiated a review for approving a combination therapy of rivoceranib and camrelizumab as the first-line treatment for hepatocellular carcinoma (HCC).The company filed a new drug application (NDA) in May.HLB Group Chairman Jin Yang-gon said on
GI Innovation expressed its intention to pursue a license out deal for GI-301, an allergy treatment, with Japanese companies at a press conference at the Grand InterContinental Seoul Parnas Hotel, in southern Seoul, on Monday. "We are currently in talks with three Japanese pharmaceutical companies t
Boehringer Ingelheim has launched Esgliteo (empagliflozin/linagliptin), a compound therapy of the SGLT-2 inhibitor Jardiance (empagliflozin) and the DPP-4 inhibitor Trajenta (linagliptin), with insurance coverage in Korea.Boehringer Ingelheim on Monday announced the domestic launch of Esgliteo (empa
GC said it has submitted a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) for Alyglo, its 10 percent intravenous immunoglobulin.Alyglo, sold under the brand name IVIG-SN 10 percent in Korea, is a liquid immunoglobulin preparation purified from plasma fractions.Kor
Amid a protracted labor conflict at MSD Korea due to the company’s decision to abolish its general medicine (GM) division, the management has expanded the eligibility for its early retirement program (ERP) while increasing compensation money.MSD Korea recently announced the expansion of the ERP to a
"We must keep the hard-won flame alive. It is imperative to increase the self-reliance in active pharmaceutical ingredients (API) to establish pharmaceutical sovereignty by improving the self-sufficiency rate of medicines."Han Ssang-soo, who chairs the Special Committee for API within the Korea Phar